Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Citations Over TimeTop 1% of 2020 papers
Abstract
To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics. Multi-omics clustering revealed four subgroups defined by key driver mutations, country, and gender. Proteomic and phosphoproteomic data illuminated biology downstream of copy number aberrations, somatic mutations, and fusions and identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK. Immune subtyping revealed a complex landscape, reinforced the association of STK11 with immune-cold behavior, and underscored a potential immunosuppressive role of neutrophil degranulation. Smoking-associated LUADs showed correlation with other environmental exposure signatures and a field effect in NATs. Matched NATs allowed identification of differentially expressed proteins with potential diagnostic and therapeutic utility. This proteogenomics dataset represents a unique public resource for researchers and clinicians seeking to better understand and treat lung adenocarcinomas.
Related Papers
- → Proteomics and phosphoproteomics for the mapping of cellular signalling networks(2008)58 cited
- → Mass Spectrometry-Compatible Subcellular Fractionation for Proteomics(2019)29 cited
- → Integrative proteomics, phosphoproteomics and acetylation proteomics analyses of acute pancreatitis in rats(2023)5 cited
- → A Proteogenomic Approach to Unravel New Proteins Encoded in the Leishmania donovani (HU3) Genome(2024)3 cited
- Advances in computational mass spectrometry: Phosphoproteomics and proteogenomics(2008)